↓ Skip to main content

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

Overview of attention for article published in Investigational New Drugs, March 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 1,265)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
16 news outlets
patent
1 patent

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
Published in
Investigational New Drugs, March 2023
DOI 10.1007/s10637-023-01342-x
Pubmed ID
Authors

Antonio Jimeno, Joaquina Baranda, Wade T. Iams, Jong Chul Park, Monica Mita, Michael S. Gordon, Matthew Taylor, Neesha Dhani, Alexis D. Leal, Prakash Neupane, Cathy Eng, Oladapo Yeku, Alain Mita, Justin C. Moser, Marcus Butler, Scott M. Loughhead, Julia Jennings, Nathan R. Miselis, Rui-Ru Ji, Nitya Nair, Martin Kornacker, Ricardo F. Zwirtes, Howard Bernstein, Armon Sharei

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 17%
Student > Bachelor 1 17%
Unknown 4 67%
Readers by discipline Count As %
Engineering 1 17%
Unknown 5 83%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 115. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2024.
All research outputs
#364,851
of 25,508,813 outputs
Outputs from Investigational New Drugs
#5
of 1,265 outputs
Outputs of similar age
#8,717
of 424,460 outputs
Outputs of similar age from Investigational New Drugs
#1
of 10 outputs
Altmetric has tracked 25,508,813 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,265 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,460 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them